Todd Romigh

Development and Characterization of Triazole-Based WDR5 Inhibitors for the Treatment of Glioblastoma

This study develops triazole-based WDR5 inhibitors that show improved brain penetration and antiproliferative activity against glioblastoma CSCs, with synergistic effects when combined with ATAD2 inhibitors.

Fragment-Based Development of NSP14 Exonuclease Inhibitors Confounded by Batch-to-Batch Variability

The paper identifies false positive inhibitors of NSP14 ExoN due to contaminating divalent cations, highlighting challenges in fragment-based drug development for this target.

Mechanism and Structure-Guided Optimization of SLC1A1/EAAT3-Selective Inhibitors in Kidney Cancer

This study determines the cryo-EM structure of SLC1A1 bound to an inhibitor, identifies its binding mechanism, and develops improved inhibitors with enhanced cytotoxicity in kidney cancer cells.

XPC loss-of-function triggers melanomagenesis through CDKN2A downregulation

This study identifies an XPC variant that promotes melanomagenesis by downregulating CDKN2A through promoter binding, independent of its nucleotide excision repair function.

Redefining the PTEN Promoter: Identification of Two Upstream Transcription Start Regions

The paper identifies two new transcription start regions (TSRs) upstream of the PTEN promoter, expanding its regulatory landscape and suggesting potential clinical implications for PTEN-related disorders.